A New Vaccine Candidate Strain of Coxsackievirus B5 Selected on the Basis of its Biological Properties

Abstract

Objective: Evidence indicates that coxsackievirus B5 (CVB5) can cause meningitis, and hand, foot, and mouth disease (HFMD), and is associated with type 1 diabetes. No effective drug or vaccine is available for treating CVB5 infections or controlling outbreaks.

Methods: The Vero-cell-adapted vaccine candidate strain KM299-L05 underwent comprehensive phylogenetic analysis, sequence alignment, assessment of virulence in BALB/c mice, Vero cell acclimation, three successive rounds of plaque purification, preparation of experimental vaccines, and immunogenicity evaluation.

Results: KM299-L05 was the most virulent strain in BALB/c mice. Its infectious titer reached 10^8.0 CCID₅₀/mL in Vero cells, and it belonged to the Chinese epidemic genotype C3. An inactivated CVB5 vaccine derived from the KM299-L05 strain produced neutralizing antibodies with a titer range from 1:384 to 1:768 against a variety of clinical CVB5 isolates, particularly the prototype strain. Maternal antibodies fully protected all examined suckling BALB/c mice against lethal challenge.

Conclusion: Although the study was limited to neonatal mice, our findings suggested that the KM299-L05 strain has potential as a novel CVB5 vaccine candidate in China, and provide a rationale for the development of a CVB5 vaccine.

Keywords

coxsackievirus B5 / Vero cell / animal model / inactivated vaccine / immunogenicity

References

[1] Hu YF, Zhao R, Xue Y, Yang F, Jin Q. Full genome sequence of a novel coxsackievirus B5 strain isolated from neurological hand, foot, and mouth disease patients in China. J Virol. 2012; 86(20): 11408-11409.

[2] Li J, Wang X, Cai J, Ge Y, Wang C, Qiu Y, et al. Non-polio enterovirus infections in children with central nervous system disorders in Shanghai, 2016-2018: serotypes and clinical characteristics. J Clin Virol. 2020; 129: 104516.

[3] Compagnoni Carmona RC, Caetano Machado B, Aparecida de Sousa C, Vieira HR, Moraes Alves MR, Farias de Souza KA, et al. Distribution of species enterovirus B in patients with central nervous system infections in São Paulo State, Brazil. J Med Virol. 2020; 92(12): 3849-3856.

[4] Chen P, Tao Z, Song Y, Liu G, Wang H, Liu Y, et al. A coxsackievirus B5-associated aseptic meningitis outbreak in Shandong Province, China in 2009. J Med Virol. 2013; 85(3): 483-489.

[5] Rao CD, Yergolkar P, Shankarappa KS. Shankarappa. Antigenic diversity of enteroviruses associated with nonpolio acute flaccid paralysis, India, 2007-2009. Emerg Infect Dis. 2012; 18(11): 1833-1840.

[6] Kim KW, Ho A, Alshabee-Akil A, Hardikar AA, Kay TW, Rawlinson WD, et al. Coxsackievirus B5 infection induces dysregulation of microRNAs predicted to target known type 1 diabetes risk genes in human pancreatic islets. Diabetes. 2016; 65(4): 996-1003.

[7] Sciandra I, Falasca F, Maida P, Tranquilli G, Di Carlo D, Mazzuti L, et al. Seroprevalence of group B coxsackieviruses: retrospective study in an Italian population. J Med Virol. 2020; 92(12): 3138-3143.

[8] Liu Y, Chen J, Zhang M, Guo W, Feng C, Liu J, et al. Coxsackievirus B: the important agent of hand, foot, and mouth disease. J Med Virol. 2023; 95(3): e28669.

[9] Ji H, Fan H, Lu PX, Zhang XF, Ai J, Shi C, et al. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. BMC Infect Dis. 2019; 19(1): 79.

[10] Hu YF, Yang F, Du J, Zhang T, Xue Y, Jin Q. Coxsackievirus B5, associated with neurological hand, foot and mouth disease, China. J Infect. 2012; 65(2): 189-191.

[11] Moliner-Calderón E, Rabella-Garcia N, Turón-Viñas E, Ginovart-Galiana G, Figueras-Aloy J. Relevance of enteroviruses in neonatal meningitis. Enferm Infecc Microbiol Clin (Engl Ed). 2024; 42(1): 17-23.

[12] Fall A, Forman M, Morris CP, Gniazdowski V, Luo CH, Hanlon A, et al. Enterovirus characterized from cerebrospinal fluid in a cohort from the Eastern United States. J Clin Virol. 2023; 161: 105401.

[13] Chen YC, Yang SL, Yang H, Lin TY, Hsieh YC, Huang KA, et al. Clinical characteristics of echovirus 11 and coxsackievirus B5 infections in Taiwanese children requiring hospitalization. J Microbiol Immunol Infect. 2021; 54(4): 581-587.

[14] Stone VM, Hankaniemi MM, Laitinen OH, Sioofy-Khojine AB, Lin A, Diaz Lozano IM, et al. A hexavalent coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 2020; 6(19): eaaz2433.

[15] Hyöty H, Kääriäinen S, Laiho JE, Comer GM, Tian W, Härkönen T, et al. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled phase I trial. Diabetologia. 2024; 67(5): 811-821.

[16] Zhang N, Zheng T, Chen Y, Zhu H, Qu Y, Zheng H, et al. Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice. Vaccine. 2021; 39(39): 5699-5705.

[17] Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine. 1999; 17(15-16): 2059-2066.

[18] Reed Z, Cardosa MJ. Status of research and development of vaccines for enterovirus 71. Vaccine. 2016; 34(26): 2967-2970.

[19] Han Y, Chen Z, Zheng K, Li X, Kong J, Duan X, et al. Epidemiology of hand, foot, and mouth disease before and after the introduction of enterovirus 71 vaccines in Chengdu, China, 2009-2018. Pediatr Infect Dis J. 2020; 39(10): 969-978.

[20] Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007; 81(17): 9386-9395.

[21] Michel ML, Tiollais P . Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol. 2010; 58(4): 288-295.

[22] Lindberg AM, Polacek C. Molecular analysis of the prototype coxsackievirus B5 genome. Arch Virol. 2000; 145(2): 205-221.

[23] Sickles GM, Feorino P, Plager H. Isolation and type determination of coxsackie virus, group B, in tissue culture. Proc Soc Exp Biol Med. 1955; 88(1): 22-24.

[24] He Y, Wei H, Wei L, Fan H, Yan D, Zhao H, et al. Molecular epidemiology reveals the co-circulation of two genotypes of coxsackievirus B5 in China. Viruses. 2022; 14(12): 2693.

[25] Liu P, Yuan Y, Cui B, Huo Y, Bian L, Chen L, et al. Cross-antigenicity between EV71 sub-genotypes: implications for vaccine efficacy. Viruses. 2021; 13(5): 720.

[26] Liu H, Zhang M, Feng C, Cong S, Xu D, Sun H, et al. Characterization of coxsackievirus A6 strains isolated from children with hand, foot, and mouth disease. Front Cell Infect Microbiol. 2021; 11: 700191.

[27] Liu J, Zhu Y, Pan Y, Liu Z, Guo C, Ma S. Complete genome sequence analysis of two human coxsackievirus A9 strains isolated in Yunnan, China, in 2009. Virus Genes. 2015; 50(3): 358-364.

[28] Kumar S, Stecher G, Tamura K. MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016; 33: 1870-1874.

[29] Zhang M, Xu D, Liu Y, Wang X, Xu L, Gao N, et al. Screening of a new candidate coxsackievirus B1 vaccine strain based on its biological characteristics. Front Microbiol. 2023; 14: 1172349.

[30] Yin Z, Wu Y, Zhu R, Xu L, Lin Y, Yang H, et al. Development of a neonatal mouse model for coxsackievirus B1 antiviral evaluation. Virol Sin. 2021; 36(6): 1575-1584.

[31] Qian SS, Wei ZN, Jin WP, Wu J, Zhou YP, Meng SL, et al. Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model. Emerg Microbes Infect. 2021; 10(1): 763-773.

[32] Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011; 29(37): 6269-6275.

[33] Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Määttä JAE, Larsson PG, et al. Optimized production and purification of coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine. 2017; 35(30): 3718-3725.

[34] Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol. 1999; 73(3): 1941-1948.

[35] McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002; 26(1): 91-107.

[36] Moon MS, Joo CH, Hwang IS, Ye JS, Jun EJ, Lee HS, et al. Distribution of viral RNA in mouse tissues during acute phase of coxsackievirus B5 infection. Intervirology. 2005; 48(2-3): 153-160.

[37] Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L, et al. Antiviral activity of Arbidol against coxsackie virus B5 in vitro and in vivo. Arch Virol. 2009; 154(4): 601-607.

[38] Mao Q, Hao X, Hu Y, Du R, Lang S, Bian L, et al. A neonatal mouse model of central nervous system infections caused by coxsackievirus B5. Emerg Microbes Infect. 2018; 7(1): 185.

[39] Smith WG. Coxsackie B myopericarditis in adults. Am Heart J. 1970; 80(1): 34-46.

[40] Null FC, Castle CH. Adult pericarditis and myocarditis due to coxsackie virus group B, type 5. N Engl J Med. 1959; 261: 937-942.

[41] Marks MI, Joncas JH, Mauer SM. Fatal hepatitis in siblings: isolation of coxsackievirus B5 and herpes simplex virus. Can Med Assoc J. 1970; 102(13): 1391-1393 passim.

[42] Clavell M, Barkemeyer B, Martinez B, Craver R, Correa H, Gohd R, et al. Severe hepatitis in a newborn with coxsackievirus B5 infection. Clin Pediatr (Phila). 1999; 38(12): 739-741.

[43] Opare JK, Akweongo P, Afari EA, Odoom JK. Poliovirus neutralizing antibody levels among individuals in three regions of Ghana. Ghana Med J. 2019; 53(2): 170-180.

[44] Zhu W, Jin P, Li JX, Zhu FC, Liu P. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Rev Vaccines. 2017; 16(9): 945-949.